Want to see JP:6568 full AI Analyst Report?

KNC Laboratories Co.,Ltd. (6568) Price & Analysis

0 Followers

6568 Stock Chart & Stats

¥1124.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥1124.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥1,060.00 - ¥1,418.00

Previous CloseN/A

Volume3.20K

Average Volume (3M)2.89K

Market Cap

¥10.27B

Enterprise Value¥10.93K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)13.1

Beta0.57

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.98%

Share Statistics

EPS (TTM)85.36

Shares Outstanding7,779,900

10 Day Avg. Volume3,150

30 Day Avg. Volume2,890

Financial Highlights & Ratios

PEG Ratio3.29

Price to Book (P/B)0.67

Price to Sales (P/S)1.04

P/FCF Ratio-26.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)208.6

Revenue Forecast (FY)¥12.00B

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryA renewed top-line recovery (11.2% YoY in 2026) signals recovering demand and restores scale economics. Over 2–6 months this supports better capacity utilization, steadier customer relationships and provides a foundation for margin repair if cost and pricing actions follow.

Strong Balance SheetHistorically low leverage and rising equity provide a durable financial cushion. This capitalization supports investment, working-capital needs and absorption of cyclical shocks over the medium term, enabling strategic choices without immediate refinancing pressure.

Operating Cash Flow RecoveryImproved operating cash flow in 2026 indicates better cash conversion at the core business level. Sustained OCF gains can fund necessary capex or reduce reliance on external financing, and are a precondition to return to positive free cash flow if margin trends stabilize.

Bears Say

Profitability CompressionSignificant margin deterioration versus the 2023–2024 peak—gross profit fell in 2026 despite higher sales—suggests structural pressure from input costs, pricing or mix. Persisting compression undermines sustainable earnings power and limits capacity to rebuild reserves.

Negative Free Cash FlowTwo consecutive years of negative free cash flow reduce financial flexibility, constraining debt paydown, dividends and discretionary investment. If cash conversion does not improve, management may need to cut capex or take on more debt, affecting long-term growth options.

Rising Debt TrendAn upward trend in debt over 2024–2026 increases leverage risk if margins remain weak. Even with moderate historical leverage, the recent rise reduces headroom for shocks and raises interest and refinancing sensitivity over the medium term, pressuring strategic flexibility.

6568 FAQ

What was KNC Laboratories Co.,Ltd.’s price range in the past 12 months?

KNC Laboratories Co.,Ltd. lowest stock price was ¥1060.00 and its highest was ¥1418.00 in the past 12 months.

What is KNC Laboratories Co.,Ltd.’s market cap?

KNC Laboratories Co.,Ltd.’s market cap is ¥10.27B.

When is KNC Laboratories Co.,Ltd.’s upcoming earnings report date?

KNC Laboratories Co.,Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 21 days.

How were KNC Laboratories Co.,Ltd.’s earnings last quarter?

KNC Laboratories Co.,Ltd. released its earnings results on May 14, 2026. The company reported ¥85.36 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is KNC Laboratories Co.,Ltd. overvalued?

According to Wall Street analysts KNC Laboratories Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KNC Laboratories Co.,Ltd. pay dividends?

KNC Laboratories Co.,Ltd. pays a Semiannually dividend of ¥16 which represents an annual dividend yield of 2.98%. See more information on KNC Laboratories Co.,Ltd. dividends here

What is KNC Laboratories Co.,Ltd.’s EPS estimate?

KNC Laboratories Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KNC Laboratories Co.,Ltd. have?

KNC Laboratories Co.,Ltd. has 7,779,900 shares outstanding.

What happened to KNC Laboratories Co.,Ltd.’s price movement after its last earnings report?

KNC Laboratories Co.,Ltd. reported an EPS of ¥85.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.563%.

Which hedge fund is a major shareholder of KNC Laboratories Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:6568

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KNC Laboratories Co.,Ltd.

KNC Laboratories Co., Ltd. engages in research, development, and production solutions for organic chemicals. Its operations are carried out through the following business divisions: Functional Materials Business, Pharmaceutical Business, and Bio Business. The Functional Materials Business division provides display materials, chemicals for semiconductor manufacturing, carbon nanotube dispersions, etc. The Pharmaceutical Business division provides compounds for pharmaceutical research and development. The Bio Business Division provides auxiliary agents for antibody drug manufacturing. The company was founded on January 22, 1985 and is headquartered in Kobe, Japan.